{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:01:16Z","timestamp":1791478876616,"version":"4.3.4"},"reference-count":25,"publisher":"Oceanside Publications Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:p>Venom immunotherapy (VIT) with Hymenoptera venom extracts is highly effective in preventing large local, systemic allergic, and anaphylactic reactions to insect stings. VIT is not required for patients with cutaneous systemic or large local allergic reactions to stings because it is uncommon for reactions to become more severe. The clinical history, with confirmatory skin or serum tests for venom IgE, can clarify the risk for future anaphylaxis and the need for VIT. For initial treatment, rush regimens are recommended because they have the same or less risk of systemic reactions than slower traditional regimens. VIT is relatively safe with a low incidence of systemic reactions. Injection-site reactions can be bothersome but do not predict systemic reactions to venom injections. Patients who need VIT should be screened for baseline serum tryptase and possible underlying mast cell disorders. VIT can be discontinued after five years in most patients, but those with known high-risk factors should continue VIT indefinitely.<\/jats:p>","DOI":"10.2500\/aap.2022.43.210109","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T04:31:26Z","timestamp":1657600286000},"page":"339-343","source":"Crossref","is-referenced-by-count":14,"title":["Venom allergen immunotherapy"],"prefix":"10.2500","volume":"43","author":[{"given":"David B. K.","family":"Golden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/j.1398-9995.2005.00963.x","article-title":"Diagnosis of Hymenoptera venom allergy","volume":"60","author":"Bil\u00f3","year":"2005","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.anai.2016.10.031","article-title":"Stinging insect hypersensitivity: A practice parameter update 2016","volume":"118","author":"Golden","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJM197807272990401","article-title":"A controlled trial of immunotherapy in insect hypersensitivity","volume":"299","author":"Hunt","year":"1978","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/all.13262","article-title":"EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy","volume":"73","author":"Sturm","year":"2018","journal-title":"Allergy"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/j.1365-2222.2009.03324.x","article-title":"The natural history and epidemiology of insect venom allergy: clinical implications","volume":"39","author":"Bil\u00f3","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"B6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0091-6749(94)90351-4","article-title":"Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity","volume":"93","author":"Franken","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaci.2005.12.1313","article-title":"Clinical and entomological factors influence the outcome of sting challenge studies","volume":"117","author":"Golden","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199012063232305","article-title":"The value of immunotherapy with venom in children with allergy to insect stings","volume":"323","author":"Valentine","year":"1990","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jaci.2009.03.017","article-title":"Venom immunotherapy reduces large local reactions to insect stings","volume":"123","author":"Golden","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.anai.2014.05.029","article-title":"The HIT study: Hymenoptera identification test \u2013 how accurate are people at identifying stinging insects?","volume":"113","author":"Baker","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/ACI.0000000000000574","article-title":"The role of component-resolved diagnosis in Hymenoptera venom allergy","volume":"19","author":"Bil\u00f3","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaci.2010.07.031","article-title":"Honeybee venom immunotherapy in children using a 50-\u03bcg maintenance dose","volume":"127","author":"Houliston","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jaip.2016.12.031","article-title":"Rush venom immunotherapy: ready for prime time?","volume":"5","author":"Golden","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2500\/aap.2022.43.210108","article-title":"Accelerated\/rush allergen immunotherapy","volume":"43","author":"Greiwe","year":"2022","journal-title":"Allergy Asthma Proc"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(03)12827-9","article-title":"Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial","volume":"361","author":"Brown","year":"2003","journal-title":"Lancet"},{"key":"B16","first-page":"CD008838","article-title":"Venom immunotherapy for preventing allergic reactions to insect stings","volume":"10","author":"Boyle","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1398-9995.2009.02198.x","article-title":"Bee venom immunotherapy - how early is it effective?","volume":"65","author":"Goldberg","year":"2010","journal-title":"Allergy"},{"key":"B18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0091-6749(92)90319-W","article-title":"Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety","volume":"89","author":"Muller","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1067\/mai.2001.119154","article-title":"Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses","volume":"108","author":"Ru\u00ebff","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1398-9995.2009.02118.x","article-title":"Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy","volume":"64","author":"Niedoszytko","year":"2009","journal-title":"Allergy"},{"key":"B21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2500\/aap.2022.43.220035","article-title":"Safety of subcutaneous allergen immunotherapy","volume":"43","author":"Bernstein","year":"2022","journal-title":"Allergy Asthma Proc"},{"key":"B22","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased \u03b1-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1111\/all.14785","article-title":"\u03b2-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy","volume":"76","author":"Sturm","year":"2021","journal-title":"Allergy"},{"key":"B25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2500\/aap.2022.43.220026","article-title":"Allergen immunotherapy: Long-term efficacy of the sublingual and subcutaneous routes","volume":"43","author":"Penagos","year":"2022","journal-title":"Allergy Asthma Proc"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2022\/00000043\/00000004\/art00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T10:11:24Z","timestamp":1676110284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2022.43.210109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7,1]]}},"alternative-id":["1088-5412(20220701)43:4L.339;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2022.43.210109","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,1]]}}}